Pharmaceutics (Oct 2021)

Telmisartan Loaded Nanofibers Enhance Re-Endothelialization and Inhibit Neointimal Hyperplasia

  • Chen-Hung Lee,
  • Kuo-Sheng Liu,
  • Julien George Roth,
  • Kuo-Chun Hung,
  • Yen-Wei Liu,
  • Shin-Huei Wang,
  • Chi-Ching Kuo,
  • Shih-Jung Liu

DOI
https://doi.org/10.3390/pharmaceutics13111756
Journal volume & issue
Vol. 13, no. 11
p. 1756

Abstract

Read online

Stent implantation impairs local endothelial function and may be associated with subsequent adverse cardiovascular events. Telmisartan, an angiotensin II receptor blocker that has unique peroxisome proliferator-activated-receptor-gamma-mediated effects on cardiovascular disease, has been shown to enhance endothelial function and limit neointimal hyperplasia. This study utilized hybrid biodegradable/stent nanofibers to facilitate sustained and local delivery of telmisartan to injured arterial vessels. Telmisartan and poly(d,l)-lactide-co-glycolide (PLGA) (75:25) were dissolved in hexafluoroisopropyl alcohol and electrospun into biodegradable nanofibrous tubes which were coated onto metal stents. By releasing 20% of the loaded telmisartan in 30 days, these hybrid biodegradable/stent telmisartan-loaded nanofibers increased the migration of endothelial progenitor cells in vitro, promoted endothelialization, and reduced intimal hyperplasia. As such, this work provides insights into the use of PLGA nanofibers for treating patients with an increased risk of stent restenosis.

Keywords